Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera ® ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial

Published 2022 View Full Article

  1. Home
  2. Publications
  3. Publication Search
  4. Publication Details
Title
Comparison of efficacy and safety of ripertamab (SCT400) versus rituximab (Mabthera ® ) in combination with CHOP in patients with previously untreated CD20‐positive diffuse large B‐cell lymphoma: A randomized, single‐blind, phase III clinical trial
Authors
Keywords
-
Journal
HEMATOLOGICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2022-07-21
DOI
10.1002/hon.3054
References
View 5 related references

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Search
Webinars Posters Questions Hubs Funding Journals Articles Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.